Ameritas Advisory Services LLC Cuts Stake in Pfizer Inc. $PFE

Ameritas Advisory Services LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 34.6% during the second quarter, HoldingsChannel reports. The firm owned 50,311 shares of the biopharmaceutical company’s stock after selling 26,646 shares during the period. Ameritas Advisory Services LLC’s holdings in Pfizer were worth $1,220,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Vest Financial LLC increased its holdings in shares of Pfizer by 73.5% in the 1st quarter. Vest Financial LLC now owns 47,252 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 20,018 shares during the period. Signal Advisors Wealth LLC grew its stake in Pfizer by 16.6% in the first quarter. Signal Advisors Wealth LLC now owns 8,826 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 1,258 shares during the last quarter. Finally, Insight Advisors LLC PA purchased a new position in Pfizer in the first quarter valued at about $215,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.1%

NYSE:PFE opened at $27.37 on Friday. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company’s 50 day moving average is $24.67 and its two-hundred day moving average is $24.14.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Finally, UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.